GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Universal Ibogaine Inc (TSXV:IBO) » Definitions » Debt-to-Revenue

Universal Ibogaine (TSXV:IBO) Debt-to-Revenue : 1.19 (As of Jan. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Universal Ibogaine Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Universal Ibogaine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.13 Mil. Universal Ibogaine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$2.67 Mil. Universal Ibogaine's annualized Revenue for the quarter that ended in Jan. 2024 was C$2.36 Mil. Universal Ibogaine's annualized Debt-to-Revenue for the quarter that ended in Jan. 2024 was 1.19.


Universal Ibogaine Debt-to-Revenue Historical Data

The historical data trend for Universal Ibogaine's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universal Ibogaine Debt-to-Revenue Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23
Debt-to-Revenue
Get a 7-Day Free Trial N/A N/A N/A 1.62 2.70

Universal Ibogaine Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.91 1.55 1.24 1.09 1.19

Competitive Comparison of Universal Ibogaine's Debt-to-Revenue

For the Biotechnology subindustry, Universal Ibogaine's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Universal Ibogaine's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's Debt-to-Revenue falls into.



Universal Ibogaine Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Universal Ibogaine's Debt-to-Revenue for the fiscal year that ended in Jul. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.815 + 0.962) / 1.03
=2.70

Universal Ibogaine's annualized Debt-to-Revenue for the quarter that ended in Jan. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.131 + 2.666) / 2.356
=1.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jan. 2024) Revenue data.


Universal Ibogaine Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Universal Ibogaine's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Universal Ibogaine (TSXV:IBO) Business Description

Traded in Other Exchanges
Address
400 3rd Avenue South west, Suite 1470, Calgary, AB, CAN, T2P 4H2
Universal Ibogaine Inc develops a platform of addiction treatment clinics, which use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants. It runs addiction clinics it has a research partner clinic in Mexico.
Executives
Ian Rabb Senior Officer

Universal Ibogaine (TSXV:IBO) Headlines

No Headlines